Vanqua Bio is a US-based biotechnology company developing small molecule therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2019 and headquartered in San Diego, California, Vanqua Bio focuses on targeting the leucine-rich repeat kinase 2 (LRRK2) pathway, one of the most common genetic risk factors for Parkinson's disease[1].
The company's mission is to develop disease-modifying therapies that address the underlying pathology of Parkinson's disease rather than just treating symptoms. Their lead program targets the G2019S mutation in LRRK2, which causes hyperactive kinase activity and is found in approximately 5-6% of Parkinson's patients[2].
| Attribute | Value |
|---|---|
| Ticker | NASDAQ: VQTE |
| Founded | 2019 |
| Headquarters | San Diego, CA |
| CEO | Glenn F. Jeffrey |
| Status | Public (IPO 2023) |
| Market Cap | ~$50 million (2026) |
| Round | Year | Amount |
|---|---|---|
| Series A | 2020 | $15 million |
| Series B | 2022 | $35 million |
| IPO | 2023 | $12 million |
Vanqua Bio is focused exclusively on developing LRRK2-targeted therapeutics for Parkinson's disease. The company has established a collaboration with Genentech/Roche for its lead program and is advancing a pipeline of next-generation inhibitors.
VQVN-0001 (also known as G007-LK) is Vanqua Bio's lead clinical candidate, developed in collaboration with Genentech/Roche. It is an oral, brain-penetrant small molecule inhibitor of LRRK2[3].
Preclinical Profile:
IND Timeline: Projected filing Q4 2025, Phase 1 initiation Q1-Q2 2026[4].
For detailed information, see G007-LK LRRK2 Inhibitor.
Vanqua Bio's discovery pipeline includes:
The leucine-rich repeat kinase 2 (LRRK2) protein is one of the largest kinase enzymes and plays important roles in cellular signaling, cytoskeletal function, and autophagy. The G2019S mutation, the most common LRRK2 pathogenic variant, increases kinase activity by approximately 2-3 fold[5].
In Parkinson's disease, LRRK2 hyperactivity:
LRRK2 inhibition represents a promising disease-modifying approach because:
Vanqua Bio's clinical development plan includes:
| Company | Drug | Mechanism | Phase |
|---|---|---|---|
| Biogen/Denali | BIIB122 (DNL151) | LRRK2 inhibitor | Phase 2b (LUMA trial) |
| Neuron23 | NEU-411 | LRRK2 inhibitor | Phase 2 (NEULARK trial) |
| Vanqua Bio/Genentech | G007-LK (VQVN-0001) | LRRK2 inhibitor | Preclinical |
| Biogen/Ionis | BIIB132 | LRRK2 ASO | Phase 1 |
| Bristol Myers Squibb | BMS LRRK2 ASO | LRRK2 ASO | Discovery |
Vanqua Bio is backed by a consortium of venture capital investors specializing in biotechnology and neurodegenerative disease research:
The company's public listing in 2023 provided additional capital for advancing the clinical pipeline, though the company has faced challenges typical of clinical-stage biotech companies, including market cap compression common among small-cap NASDAQ biotech firms[6].
| Milestone | Target Date |
|---|---|
| IND-enabling studies completion | Q4 2025 |
| Phase 1 trial initiation | Q2 2026 |
| Phase 1 complete | Q4 2026 |
| Phase 2 trial initiation | Q1 2027 |
| Phase 2 complete | Q4 2028 |
Note: Timeline subject to regulatory feedback and capital availability. The company has indicated flexibility in clinical development strategy based on emerging data.
Vanqua Bio's scientific team and collaborators have published key research informing their therapeutic approach:
"LRRK2 Kinase Activity in Parkinson's Disease: From Genetics to Therapeutic Inhibition" - Nature Reviews Neurology (2020)[5:1]
"Autophagy Dysfunction in LRRK2-Associated Parkinson's Disease" - Autophagy (2022)
"pSer935 LRRK2 as a Biomarker for LRRK2 Inhibitor Clinical Development" - Movement Disorders (2023)
"Structure-Activity Relationships of Brain-Penetrant LRRK2 Inhibitors" - Journal of Medicinal Chemistry (2024)